←Back to Expert Scholars
Translational Medicine / 转化医学Lung Oncogenic Fusions
Alexander Drilon
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Chief, Early Drug Development Service
78
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Alexander Drilon led pivotal trials of selpercatinib, larotrectinib, and entrectinib for fusion-driven NSCLC. His work defined clinical development pathways for RET, ROS1 and NTRK inhibitors. He continues leading next-generation trials for resistance in fusion-positive disease.
Share:
🧪Research Fields 研究领域
ROS1 fusions
RET fusions
NTRK fusions
Selective inhibitors
Targeted therapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Alexander Drilon 的研究动态
Follow Alexander Drilon's research updates
留下邮箱，当我们发布与 Alexander Drilon（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment